Physician profile
Jun Liu
NPI 1184019903
$6,654.99
in general payments reported to CMS, 2019-2025
27 companies · $1,499 in 2025
The $1,499 reported for 2025 was more than what 86% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $585 · 2020: $316 · 2021: $442 · 2022: $847 · 2023: $1,288 · 2024: $1,678 · 2025: $1,499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,353 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,353.29 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,001.05 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $890.16 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Corium, LLC | $786.70 | 2022-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $602.02 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $553.80 | 2020-2025 | Uzedy, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $516.14 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $431.71 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $318.22 | 2021-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $243.05 | 2019-2025 | Fanapt, Hetlioz |
| Almatica Pharma LLC | $233.98 | 2021-2024 | Loreev Xr |
| Axsome Therapeutics, INC. | $225.88 | 2022-2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $127.09 | 2019 | |
| Allergan, INC. | $99.35 | 2019-2020 | |
| Alkermes, INC. | $92.12 | 2021-2025 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $75.05 | 2023-2025 | Quviviq, Quviviq |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $69.94 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $66.77 | 2021-2025 | Nuplazid |
| Sunovion Pharmaceuticals INC. | $59.63 | 2021 | |
| Bausch Health US, LLC | $56.53 | 2019-2020 | |
| Tris Pharma INC | $53.87 | 2023-2025 | Dyanavel Xr |
| Shire North American Group INC | $39.92 | 2019 | |
| Ironshore Pharmaceuticals INC. | $33.21 | 2024 | |
| Avion Pharmaceuticals | $21.26 | 2023 | Methylphenidate Hydrochloride |
| E.R. Squibb & Sons, L.L.C. | $19.21 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $13.84 | 2025 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $12.27 | 2019 | |
| Adlon Therapeutics L.P. | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.